CN114457130A - Recombinant engineering bacterium and construction method and application thereof - Google Patents
Recombinant engineering bacterium and construction method and application thereof Download PDFInfo
- Publication number
- CN114457130A CN114457130A CN202111135111.XA CN202111135111A CN114457130A CN 114457130 A CN114457130 A CN 114457130A CN 202111135111 A CN202111135111 A CN 202111135111A CN 114457130 A CN114457130 A CN 114457130A
- Authority
- CN
- China
- Prior art keywords
- recombinant
- pantolactone
- recombinant vector
- lactone
- dehydrogenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01168—2-Dehydropantolactone reductase (A-specific) (1.1.1.168)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01169—2-Dehydropantoate 2-reductase (1.1.1.169), i.e. ketopantoate-reductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01002—Formate dehydrogenase (1.2.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a recombinant engineering bacterium, a construction method and application thereof, wherein the recombinant engineering bacterium is induced to efficiently express L-pantolactone dehydrogenase, ketopantolactone reductase, glucose dehydrogenase and D-pantolactone hydrolase, and efficiently convert DL-pantolactone to generate the D-pantolactone. The recombinant engineering bacteria of the invention improve the selectivity of L-pantolactone dehydrogenase, obviously improve the purity and quality of D-pantolactone, the reaction efficiency and the resource utilization rate, and have the advantages of simple operation, environmental protection, higher cost and the like.
Description
Technical Field
The invention relates to the technical field of genetic engineering, in particular to a recombinant engineering bacterium, a construction method and application thereof.
Background
D-pantoic acid lactone is a medical intermediate for synthesizing vitamin medicine D-panthenol and neurotrophic medicine D-calcium homopantothenate, is used as a synthetic precursor of feed additives and daily chemical products, and has annual output of more than ten thousand tons.
DL-pantoic acid lactone is usually prepared by a chemical synthesis method, and the prepared DL-pantoic acid lactone is converted into D-pantoic acid lactone by resolution. The method for obtaining the D-pantolactone by resolving the DL-pantolactone by a microbial enzyme method comprises the following steps: 1) d-pantoic acid lactone or L-pantoic acid lactone in the DL-pantoic acid lactone is selectively hydrolyzed by microbial enzyme to obtain L-pantoic acid lactone and D-pantoic acid or L-pantoic acid and D-pantoic acid lactone; 2) extracting the mixed solution by using an organic reagent to realize the separation of L-pantolactone and D-pantoic acid; 3) d-pantoic acid is subjected to lactonization to obtain D-pantoic acid lactone, and L-pantoic acid lactone is subjected to chemical racemization to be changed into DL-pantoic acid lactone again and then is split. This method has the following drawbacks: firstly, the separation steps are multiple, and the separation efficiency is low; secondly, a great amount of pigment and other impurities are generated in the chemical racemization process, and the D-pantoic acid lactone prepared by splitting has darker color and poorer appearance quality; thirdly, chemical racemization can generate a large amount of sulfate, form solid waste and cause environmental pollution.
CN110423717A discloses a multienzyme recombinant cell and a method for synthesizing D-pantolactone by multienzyme cascade catalysis, which converts D, L-pantolactone into ketopantolactone and further generates D-pantolactone by expressing L-pantolactone dehydrogenase, ketopantolactone reductase and glucose dehydrogenase by the recombinant cell. This method has the following drawbacks: the L-pantolactone dehydrogenase has poor selectivity on L-pantolactone and catalytic reaction thereof, and can catalyze the L-pantolactone to generate ketopantolactone and D-pantolactone to generate ketopantolactone, wherein the L-pantolactone and the D-pantolactone compete to combine with an active site of the L-pantolactone dehydrogenase simultaneously, and the D-pantolactone is involved in cyclic reaction, so that the enzyme activity is reduced; when the content of L-pantolactone in a substrate is low, the L-pantolactone dehydrogenase cannot be effectively contacted with the L-pantolactone dehydrogenase, complete conversion is difficult, so that the prepared product contains the L-pantolactone, the purification difficulty is increased, and the product quality is difficult to ensure.
Therefore, how to develop a recombinant vector and engineering bacteria thereof which have high selectivity and are beneficial to improving the purity and quality of D-pantoic acid lactone, the reaction efficiency, the resource utilization rate and the like becomes an aspect which needs to be solved urgently in the field.
Disclosure of Invention
The invention aims to provide a recombinant vector which contains a recombinant vector, wherein the recombinant vector contains a nucleotide sequence of an L-pantoate lactone dehydrogenase modified gene sequence shown as SEQ ID No.1, a nucleotide sequence of a ketopantoate lactone reductase modified gene sequence shown as SEQ ID No.2, a nucleotide sequence of a glucose dehydrogenase modified gene sequence shown as SEQ ID No.3 and a nucleotide sequence of a D-pantoate lactone hydrolase modified gene sequence shown as SEQ ID No. 4.
In the preferred technical scheme of the invention, the nucleotide sequence of the L-pantolactone dehydrogenase modified gene sequence is shown as SEQ ID NO.1, the nucleotide sequence of the ketopantolactone reductase modified gene sequence is shown as SEQ ID NO.2, the nucleotide sequence of the glucose dehydrogenase modified gene sequence is shown as SEQ ID NO.3, and the nucleotide sequence of the D-pantolactone hydrolase modified gene sequence is shown as SEQ ID NO.4 on the first recombinant vector, the second recombinant vector, the third recombinant vector and the fourth recombinant vector respectively.
In a preferred technical scheme of the present invention, the recombinant vector optionally includes any one of a fifth recombinant vector or a sixth recombinant vector, wherein the fifth recombinant vector comprises a nucleotide sequence of an L-pantoate lactone dehydrogenase-modified gene sequence shown in SEQ ID No.1 and a nucleotide sequence of a ketopantoate lactone reductase-modified gene sequence shown in SEQ ID No.2, the sixth recombinant vector comprises a nucleotide sequence of an L-pantoate lactone dehydrogenase-modified gene sequence shown in SEQ ID No.1, a nucleotide sequence of a ketopantoate lactone reductase-modified gene sequence shown in SEQ ID No.2, a nucleotide sequence of a glucose dehydrogenase-modified gene sequence shown in SEQ ID No.3, and a nucleotide sequence of a D-pantoate lactone hydrolase-modified gene sequence shown in SEQ ID No. 4.
In the preferable technical scheme of the invention, the recombinant vector is used for preparing D-pantolactone from DL-pantolactone.
In the preferable technical scheme of the invention, the L-pantoate lactone dehydrogenase encoding gene is subjected to codon optimization to obtain an L-pantoate lactone dehydrogenase modified gene sequence.
In a preferred technical scheme of the invention, the coding gene of the L-pantoate lactone dehydrogenase is derived from any one of rhodococcus erythropolis, mycobacterium, nocardia, streptomycete and actinomycetes.
In the preferable technical scheme of the invention, the L-pantoate lactone dehydrogenase modified gene sequence is artificially synthesized and added with enzyme cutting sites to prepare a target gene 1, and the nucleotide sequence of the target gene 1 is shown as SEQ ID NO. 1.
In a preferred embodiment of the present invention, the enzyme cleavage site is selected from any one of XhoI and NdeI, or a combination thereof.
In the preferred technical scheme of the invention, the ketopantoate lactone reductase encoding gene is subjected to codon optimization and enzyme cutting sites to obtain a ketopantoate lactone reductase modified gene sequence.
In a preferred technical scheme of the invention, the ketopantoate lactone reductase coding gene is derived from any one of candida magnoliae, micromonospora and streptomyces.
In the preferred technical scheme of the invention, the ketopantoate lactone reductase modified gene sequence is artificially synthesized to prepare a target gene 2, and the nucleotide sequence of the target gene 2 is shown as SEQ ID NO. 2.
In a preferred embodiment of the present invention, the cleavage site is selected from SacI and NotI, or a combination thereof.
In the preferred technical scheme of the invention, the glucose dehydrogenase encoding gene is subjected to codon optimization to obtain a glucose dehydrogenase modified gene sequence.
In a preferred embodiment of the present invention, the glucose dehydrogenase encoding gene is derived from any one of Burkholderia, Escherichia coli and Aeromonas.
In the preferred technical scheme of the invention, the glucose dehydrogenase modified gene sequence is artificially synthesized and added with enzyme cutting sites to prepare a target gene 3, and the nucleotide sequence of the target gene 3 is shown as SEQ ID NO. 3.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI or a combination thereof.
In the preferred technical scheme of the invention, the D-pantolactone hydrolase coding gene is subjected to codon optimization to obtain a D-pantolactone modified gene sequence.
In a preferred technical scheme of the invention, the D-pantoate lactone hydrolase coding gene is derived from any one of fusarium moniliforme, fusarium solani and fusarium.
In the preferred technical scheme of the invention, the D-pantoic acid lactone hydrolase modification gene sequence is artificially synthesized and added with enzyme cutting sites to prepare a target gene 4, and the nucleotide sequence of the target gene 4 is shown as SEQ ID NO. 4.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI, or a combination thereof.
In a preferred embodiment of the present invention, the codon optimization is performed according to the codon preference of E.coli.
In a preferred embodiment of the present invention, the vector for recombination is selected from any one of pET-21a plasmid, pET-28a plasmid, pRSFDuet-I plasmid, or a combination thereof.
In a preferred embodiment of the present invention, the method for obtaining the first recombinant vector comprises the following steps: modifying a gene sequence or a target gene 1 of L-pantoate lactone dehydrogenase or a gene sequence shown as SEQ ID NO: 1 into a first vector to obtain a first recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the second recombinant vector comprises the following steps: the ketopantoate lactone reductase is modified into a gene sequence or a target gene 2 or a gene sequence shown as SEQ ID NO: 2 into a second vector to obtain a second recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the third recombinant vector comprises the following steps: modifying a glucose dehydrogenase gene sequence or a target gene 3 or a gene sequence shown as SEQ ID NO: 3 into a third vector to obtain a third recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fourth recombinant vector comprises the following steps: modifying a D-pantoic acid lactone hydrolase modified gene sequence or a target gene 4 or a gene sequence shown as SEQ ID NO: 4 into a fourth vector to obtain a fourth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fifth recombinant vector comprises the following steps: modifying a gene sequence or a target gene 1 of L-pantoate lactone dehydrogenase or a gene sequence shown as SEQ ID NO: 1 and ketopantoate lactone reductase modified gene sequence or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2 into a fifth vector to obtain a fifth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fifth recombinant vector comprises the following steps: firstly, modifying a gene sequence or a target gene 1 of L-pantoate lactone dehydrogenase or a gene sequence shown as SEQ ID NO: 1 into a fifth vector, and then transforming the ketopantoate lactone reductase gene sequence or the target gene 2 or the nucleotide sequence shown as SEQ ID NO: 2 into a fifth vector to obtain a fifth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fifth recombinant vector comprises the following steps: firstly, ketopantoate lactone reductase is modified to a gene sequence or a target gene 2 or a gene sequence shown as SEQ ID NO: 2 to a fifth vector, and then modifying the gene sequence of the L-pantoate lactone dehydrogenase or the target gene 1 or the nucleotide sequence shown as SEQ ID NO: 1 into a fifth vector to obtain a fifth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the sixth recombinant vector comprises the following steps: modifying a gene sequence or a target gene 1 of L-pantoate lactone dehydrogenase or a gene sequence shown as SEQ ID NO: 1, ketopantoate lactone reductase modified gene sequence or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2, glucose dehydrogenase modified gene sequence or target gene 3 or the nucleotide sequence shown in SEQ ID NO: 3, D-pantolactone hydrolase modification gene sequence or target gene 4 or a nucleotide sequence shown as SEQ ID NO: 4 into a sixth vector to obtain a sixth recombinant vector, wherein the cloning sequence of the 4 genes or the nucleotide sequences is not shown in sequence.
Another object of the present invention is to provide a recombinant engineered bacterium comprising any one or combination of a first recombinant vector capable of expressing L-pantolactone dehydrogenase, a second recombinant vector expressing ketopantolactone reductase, a third recombinant vector expressing glucose dehydrogenase and a fourth recombinant vector expressing D-pantolactone hydrolase;
and/or the recombinant engineering bacteria comprise a fifth recombinant vector capable of co-expressing L-pantoate lactone dehydrogenase and ketopantoate lactone reductase;
and/or the recombinant engineering bacteria comprise a sixth recombinant vector capable of co-expressing L-pantoate lactone dehydrogenase, ketopantoate lactone reductase, glucose dehydrogenase and D-pantoate lactone hydrolase.
In a preferred technical scheme of the invention, the recombinant engineering bacteria comprise a fifth recombinant vector capable of co-expressing L-pantoate lactone dehydrogenase and ketopantoate lactone reductase and a third recombinant vector for expressing glucose dehydrogenase.
In a preferred technical scheme of the invention, the recombinant engineering bacteria also comprise a fourth recombinant vector for expressing D-pantolactone hydrolase, or are combined with second recombinant engineering bacteria for expressing the fourth recombinant vector of the D-pantolactone hydrolase.
In the preferable technical scheme of the invention, the recombinant engineering bacteria are used for preparing D-pantolactone from DL-pantolactone.
In a preferred technical scheme of the invention, the first recombinant vector comprises an L-pantoate lactone dehydrogenase modified gene sequence.
In the preferred technical scheme of the invention, the L-pantoate lactone dehydrogenase encoding gene is subjected to codon optimization to obtain an L-pantoate lactone dehydrogenase modified gene sequence.
In a preferred technical scheme of the invention, the coding gene of the L-pantoate lactone dehydrogenase is derived from any one of rhodococcus erythropolis, mycobacterium, nocardia, streptomycete and actinomycetes.
In the preferable technical scheme of the invention, the L-pantoate lactone dehydrogenase modified gene sequence is artificially synthesized and added with enzyme cutting sites to prepare a target gene 1, and the nucleotide sequence of the target gene 1 is shown as SEQ ID NO. 1.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI or a combination thereof.
In a preferred embodiment of the present invention, the second recombinant vector comprises a ketopantoate lactone reductase-modified gene sequence.
In the preferred technical scheme of the invention, the ketopantoate lactone reductase encoding gene is subjected to codon optimization to obtain a ketopantoate lactone reductase modified gene sequence.
In a preferred technical scheme of the invention, the ketopantoate lactone reductase coding gene is derived from any one of candida magnoliae, micromonospora and streptomyces
In the preferred technical scheme of the invention, the ketopantoate lactone reductase modified gene sequence is artificially synthesized and added with enzyme cutting sites to prepare a target gene 2, and the nucleotide sequence of the target gene 2 is shown as SEQ ID NO. 2.
In a preferred embodiment of the present invention, the cleavage site is selected from SacI and NotI, or a combination thereof.
In a preferred embodiment of the present invention, the third recombinant vector comprises a glucose dehydrogenase-modified gene sequence.
In the preferred technical scheme of the invention, the glucose dehydrogenase encoding gene is subjected to codon optimization to obtain a glucose dehydrogenase modified gene sequence.
In a preferred embodiment of the present invention, the glucose dehydrogenase encoding gene is derived from any one of Burkholderia, Escherichia coli and Aeromonas.
In the preferred technical scheme of the invention, the glucose dehydrogenase modified gene sequence is artificially synthesized and added with enzyme cutting sites to prepare a target gene 3, and the nucleotide sequence of the target gene 3 is shown as SEQ ID NO. 3.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI or a combination thereof.
In a preferred technical scheme of the invention, the third recombinant vector comprises a D-pantolactone reductase modified gene sequence.
In the preferred technical scheme of the invention, the D-pantolactone hydrolase coding gene is subjected to codon optimization to obtain a D-pantolactone modified gene sequence.
In a preferred technical scheme of the invention, the D-pantoate lactone hydrolase coding gene is derived from any one of fusarium moniliforme, fusarium solani and fusarium.
In the preferred technical scheme of the invention, the D-pantoic acid lactone hydrolase modification gene sequence is artificially synthesized and added with enzyme cutting sites to prepare a target gene 4, and the nucleotide sequence of the target gene 4 is shown as SEQ ID NO. 4.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI or a combination thereof.
In a preferred embodiment of the present invention, the codon optimization is performed according to the codon preference of E.coli.
In a preferred embodiment of the present invention, the vector for recombination is selected from any one of pET-21a plasmid, pET-28a plasmid, pRSFDuet-I plasmid, or a combination thereof.
In a preferred embodiment of the present invention, the method for obtaining the first recombinant vector comprises the following steps: modifying a gene sequence or a target gene 1 of L-pantoate lactone dehydrogenase or a gene sequence shown as SEQ ID NO: 1 into a first vector to obtain a first recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the second recombinant vector comprises the following steps: the ketopantoate lactone reductase is modified into a gene sequence or a target gene 2 or a gene sequence shown as SEQ ID NO: 2 into a second vector to obtain a second recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the third recombinant vector comprises the following steps: modifying a glucose dehydrogenase gene sequence or a target gene 3 or a gene sequence shown as SEQ ID NO: 3 into a third vector to obtain a third recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fourth recombinant vector comprises the following steps: modifying a D-pantoic acid lactone hydrolase modified gene sequence or a target gene 4 or a gene sequence shown as SEQ ID NO: 4 into a fourth vector to obtain a fourth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fifth recombinant vector comprises the following steps: modifying a gene sequence or a target gene 1 of L-pantoate lactone dehydrogenase or a gene sequence shown as SEQ ID NO: 1 and ketopantoate lactone reductase modified gene sequence or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2 into a fifth vector to obtain a fifth recombinant vector, wherein the cloning sequence of the 2 genes or the nucleic acid sequences is not divided successively.
In a preferred embodiment of the present invention, the method for obtaining the sixth recombinant vector comprises the following steps: modifying a gene sequence or a target gene 1 of L-pantoate lactone dehydrogenase or a gene sequence shown as SEQ ID NO: 1, ketopantoate lactone reductase modified gene sequence or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2, glucose dehydrogenase modified gene sequence or target gene 3 or the nucleotide sequence shown in SEQ ID NO: 3, D-pantolactone hydrolase modification gene sequence or target gene 4 or a nucleotide sequence shown as SEQ ID NO: 4 into a sixth vector to obtain a sixth recombinant vector, wherein the cloning sequence of the 4 genes or the nucleic acid sequences is not shown in sequence.
In a preferred technical scheme of the invention, any one or a combination of a first recombinant vector, a second recombinant vector, a third recombinant vector, a fourth recombinant vector, a fifth recombinant vector or a sixth recombinant vector is sequentially or synchronously introduced into a host cell to obtain the recombinant engineering bacterium.
In a preferred embodiment of the present invention, the host cell is any one selected from the group consisting of bacillus, yeast, escherichia, pantoea, salmonella, corynebacterium glutamicum, escherichia coli, and pantoea ananatis.
In a preferred technical scheme of the invention, the induction method of the recombinant engineering bacteria comprises the following steps:
s-1, inoculating the recombinant engineering bacteria into an LB culture medium according to the inoculation amount of 1-5%, and culturing for 6-16h at the temperature of 30-40 ℃ and at the speed of 50-500rpm to obtain a first-stage seed solution;
s-2, inoculating the primary seed solution into a TB culture medium according to the inoculation amount of 1-5%, culturing for 6-20h at the temperature of 25-40 ℃ and at the speed of 50-500rpm, centrifuging, washing with a phosphate buffer solution, and collecting thalli.
In the preferred technical scheme of the invention, the fermentation temperature in the S-1 step is 35-38 ℃, and the rotation speed is 100-300 rpm.
In the preferable technical scheme of the invention, in the S-2 step, the culture is firstly carried out for 0.5-3h under the conditions of 35-38 ℃ and 100-300rpm, and then the culture is carried out for 10-15h under the conditions of 28-30 ℃ and 100-300 rpm.
In the preferable technical scheme of the invention, the LB culture medium comprises antibiotics, yeast powder, tryptone and sodium chloride.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 50-200mg/L of antibiotic, 4-6g/L of yeast powder, 8-12 g/L of tryptone and 8-12 g/L of sodium chloride.
In a preferred technical scheme of the invention, the antibiotic is selected from any one of penicillin, amphotericin B, nystatin, polymyxin B, streptomycin, gentamicin, tetracycline, neomycin, ampicillin and kanamycin or a combination thereof.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 100mg/L kanamycin, 5g/L yeast powder, 10g/L tryptone and 10g/L sodium chloride.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 50mg/L of ampicillin, 100mg/L of kanamycin, 5g/L of yeast powder, 10g/L of tryptone and 10g/L of sodium chloride.
In the preferable technical scheme of the invention, the TB culture medium comprises antibiotics, tryptone, yeast powder, sodium chloride, glucose and lactose.
In the preferable technical scheme of the invention, the TB culture medium comprises 50-200mg/L of antibiotic, 18-22g/L of tryptone, 4-6g/L of yeast powder, 4-6g/L of sodium chloride, 1-3g/L of glucose and 0.1-3.0g/L of lactose.
In a preferred technical scheme of the invention, the antibiotic is selected from any one of penicillin, amphotericin B, nystatin, polymyxin B, streptomycin, gentamicin, tetracycline, neomycin, ampicillin and kanamycin or a combination thereof.
In the preferable technical scheme of the invention, the composition of the TB culture medium comprises 100mg/L kanamycin, 20g/L tryptone, 5g/L yeast powder, 5g/L sodium chloride, 2g/L glucose and 0.1-2.0g/L lactose.
In the preferable technical scheme of the invention, the composition of the TB culture medium comprises 50mg/L of ampicillin, 100mg/L of kanamycin, 20g/L of tryptone, 5g/L of yeast powder, 5g/L of sodium chloride, 2g/L of glucose and 0.1-2.0g/L of lactose.
The invention also aims to provide a construction method of the recombinant engineering bacteria, which comprises the following steps:
(1) introducing any one or combination sequence of an L-pantolactone dehydrogenase modification gene sequence, a ketopantolactone reductase modification gene sequence, a glucose dehydrogenase modification gene sequence and a D-pantolactone hydrolase modification gene sequence into a vector to obtain a recombinant vector;
(2) and (3) introducing the obtained recombinant vector into a host cell to obtain the recombinant engineering bacterium.
In a preferred technical scheme of the invention, the recombinant vector is selected from a fifth recombinant vector which comprises any one of the nucleotide sequence of the L-pantoate lactone dehydrogenase modifying gene sequence shown as SEQ ID No.1 and the nucleotide sequence of the ketopantoate lactone reductase modifying gene sequence shown as SEQ ID No.2, a third recombinant vector which comprises any one of the nucleotide sequence of the glucose dehydrogenase modifying gene sequence shown as SEQ ID No.3 and a fourth recombinant vector which comprises any one of the nucleotide sequence of the D-pantoate lactone hydrolase modifying gene sequence shown as SEQ ID No. 4.
In a preferred embodiment of the present invention, the method for obtaining the third recombinant vector comprises the following steps: modifying a glucose dehydrogenase gene sequence or a target gene 3 or a gene sequence shown as SEQ ID NO: 3 into a third vector to obtain a third recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fourth recombinant vector comprises the following steps: modifying a D-pantoic acid lactone hydrolase modified gene sequence or a target gene 4 or a gene sequence shown as SEQ ID NO: 4 into a fourth vector to obtain a fourth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fifth recombinant vector comprises the following steps: modifying a gene sequence or a target gene 1 of L-pantoate lactone dehydrogenase or a gene sequence shown as SEQ ID NO: 1 and ketopantoate lactone reductase modified gene sequence or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2 into a fifth vector to obtain a fifth recombinant vector, wherein the cloning sequence of the two genes or nucleic acid sequences is not shown in sequence.
In a preferred embodiment of the present invention, the vector for recombination is selected from any one of pET-21a plasmid, pET-28a plasmid, pRSFDuet-I plasmid, or a combination thereof.
In a preferred technical scheme of the invention, any one or a combination of a third recombinant vector, a fourth recombinant vector or a fifth recombinant vector is sequentially or synchronously introduced into a host cell to obtain the recombinant engineering bacteria.
In a preferred technical scheme of the invention, the recombinant engineering bacteria comprise a fifth recombinant vector capable of co-expressing L-pantoate lactone dehydrogenase and ketopantoate lactone reductase and a third recombinant vector for expressing glucose dehydrogenase.
In a preferable technical scheme of the invention, the recombinant engineering bacteria also comprise a fourth recombinant vector for expressing the D-pantoic lactone hydrolase, or are combined with second recombinant engineering bacteria for expressing the fourth recombinant vector of the D-pantoic lactone hydrolase.
In a preferred embodiment of the present invention, the host cell is any one selected from the group consisting of bacillus, yeast, escherichia, pantoea, salmonella, corynebacterium glutamicum, escherichia coli, and pantoea ananatis.
The invention also aims to provide an induced expression method of the recombinant engineering bacteria, which comprises the following steps:
s-1, inoculating the recombinant engineering bacteria into an LB culture medium according to the inoculation amount of 1-5%, and culturing for 6-16h at the temperature of 30-40 ℃ and at the speed of 50-500rpm to obtain a first-stage seed solution;
s-2, inoculating the primary seed solution into a TB culture medium according to the inoculation amount of 1-5%, culturing for 6-20h at the temperature of 25-40 ℃ and at the speed of 50-500rpm, centrifuging, washing with a phosphate buffer solution, and collecting thalli.
In the preferred technical scheme of the invention, in the step S-1, the fermentation temperature is 35-38 ℃, and the rotation speed is 100-300 rpm.
In the preferred technical scheme of the invention, the S-2 step is firstly cultured for 0.5-3h under the conditions of 35-38 ℃ and 100-300rpm and then cultured for 10-15h under the conditions of 28-30 ℃ and 100-300 rpm.
In the preferable technical scheme of the invention, the LB culture medium comprises antibiotics, yeast powder, tryptone and sodium chloride.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 50-200mg/L of antibiotic, 4-6g/L of yeast powder, 8-12 g/L of tryptone and 8-12 g/L of sodium chloride.
In a preferred technical scheme of the invention, the antibiotic is selected from any one of penicillin, amphotericin B, nystatin, polymyxin B, streptomycin, gentamicin, tetracycline, neomycin, ampicillin and kanamycin or a combination thereof.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 100mg/L kanamycin, 5g/L yeast powder, 10g/L tryptone and 10g/L sodium chloride.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 50mg/L of ampicillin, 100mg/L of kanamycin, 5g/L of yeast powder, 10g/L of tryptone and 10g/L of sodium chloride.
In the preferable technical scheme of the invention, the TB culture medium comprises antibiotics, tryptone, yeast powder, sodium chloride, glucose and lactose.
In the preferable technical scheme of the invention, the TB culture medium comprises 50-200mg/L of antibiotic, 18-22g/L of tryptone, 4-6g/L of yeast powder, 4-6g/L of sodium chloride, 1-3g/L of glucose and 0.1-3.0g/L of lactose.
In a preferred technical scheme of the invention, the antibiotic is selected from any one of penicillin, amphotericin B, nystatin, polymyxin B, streptomycin, gentamicin, tetracycline, neomycin, ampicillin and kanamycin or a combination thereof.
In the preferable technical scheme of the invention, the composition of the TB culture medium comprises 100mg/L kanamycin, 20g/L tryptone, 5g/L yeast powder, 5g/L sodium chloride, 2g/L glucose and 0.1-2.0g/L lactose.
In the preferable technical scheme of the invention, the composition of the TB culture medium comprises 50mg/L of ampicillin, 100mg/L of kanamycin, 20g/L of tryptone, 5g/L of yeast powder, 5g/L of sodium chloride, 2g/L of glucose and 0.1-2.0g/L of lactose.
Another object of the present invention is to provide a process for the preparation of D-pantolactone, comprising the steps of: putting DL-pantolactone with the concentration of 10-300g/L into a reaction system with glucose and the OD value of recombinant engineering bacteria of 1-5, and reacting for 20-40h at the temperature of 30-40 ℃ and under the condition of pH5-7 to prepare the D-pantolactone.
In the preferable technical scheme of the invention, the OD value of the recombinant engineering bacteria is 2-3.
In the preferable technical scheme of the invention, the recombinant engineering bacteria can express L-pantolactone dehydrogenase, ketopantolactone reductase and glucose dehydrogenase.
In the preferred technical scheme of the invention, recombinant engineering bacteria for expressing D-pantolactone hydrolase can be added.
In the preferred technical scheme of the invention, the reaction solution is filtered, the filtrate is collected, the pH is adjusted to 1-3, and the mixture is placed.
In a preferred embodiment of the present invention, DL-pantoic acid lactone: the molar ratio of formic acid is 1 (0.8-1.2), preferably 1 (0.9-1.1).
In a preferred embodiment of the present invention, the concentration of DL-pantoic acid lactone is 50-250g/L, preferably 100-200 g/L.
In the preferred technical scheme of the invention, the temperature of the reaction system is 35-37 ℃.
In the preferred technical scheme of the invention, the reaction time is 25-35 h.
In the preferred technical scheme of the invention, the pH of the reaction system is 5.5-6.5, and preferably 5.8-6.2.
In a preferred embodiment of the present invention, the pH adjuster is selected from any one of ammonia water, sodium hydroxide, sodium bicarbonate, triethylamine, potassium hydroxide, sodium phosphate, sodium citrate, sodium malate, phosphate buffer, Tris buffer, and sulfuric acid.
In a preferred embodiment of the present invention, NADPH is optionally added, and preferably, the concentration of NADPH in the reaction system is 10 to 100mmol/L, preferably 30 to 90mmol/L, and more preferably 50 to 70 mmol/L.
In the preferred technical scheme of the invention, the ee value of the obtained D-pantolactone is more than or equal to 95 percent, preferably more than or equal to 96 percent, more preferably more than or equal to 97 percent, still more preferably more than or equal to 98 percent, and still more preferably more than or equal to 99 percent.
The invention also aims to provide application of the recombinant engineering bacteria in preparing D-pantolactone from DL-pantolactone.
In a preferred embodiment of the present invention, the use of said D-pantolactone for the preparation of a panto-compound, preferably said panto-compound is selected from any one of D-pantolactone, D-pantothenic acid, D-calcium pantothenate, D-panthenol, pantethine.
Unless otherwise indicated, when the present invention relates to percentages between liquids, said percentages are volume/volume percentages; the invention relates to the percentage between liquid and solid, said percentage being volume/weight percentage; the invention relates to the percentages between solid and liquid, said percentages being weight/volume percentages; the balance being weight/weight percent.
1. Conversion rate
Instruments and working conditions: shimadzu LC-16 liquid chromatograph and chromatographic column
IE5 μm, 4.6 × 250mm, column temperature 30 deg.C, collection time 30min, wavelength 210nm, flow rate 1.0ml/min, mobile phase 0.05mol/L sodium dihydrogen phosphate water solution: methanol 60: 40.
The experimental steps are as follows: respectively diluting the reaction solution by 100 times when the conversion time T is 0 and T is M (M is any value more than 0), filtering, injecting sample with the sample amount of 10ul, and respectively recording the peak area S of L-pantolactone0And SM。
Conversion rate(M time)＝(S0-SM)/S0。
2. ee value calculation formula
ee value ═ L-pantolactone content (D-pantolactone content)/(D-pantolactone content + L-pantolactone content)
Compared with the prior art, the invention has the following beneficial technical effects:
1. the invention provides a recombinant engineering bacterium and a construction method thereof, the recombinant engineering bacterium can express an L-pantolactone dehydrogenase encoding gene, a ketopantolactone reductase encoding gene and a glucose dehydrogenase encoding gene D-pantolactone hydrolase encoding gene through induction culture, is used for efficiently preparing D-pantolactone with high optical purity, and has the advantages of simple operation, environmental protection, suitability for industrial production and the like.
2. The invention also provides a method for synthesizing D-pantolactone by efficiently catalyzing DL-pantolactone or L-pantolactone by using the enzyme induced by the recombinant engineering bacteria, which obviously improves the selectivity and reaction efficiency of L-pantolactone dehydrogenase and the product conversion rate.
3. The method does not adopt a chemical resolution reagent, avoids the cyclic racemization of the L-pantoic acid lactone, shortens the production period, and has the advantages of simple and convenient operation, environmental protection, better cost, suitability for large-scale industrial production and the like.
Detailed Description
The present invention is further illustrated in detail by the following examples. These examples and experimental examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1 construction of a multienzyme Co-expression recombinant engineered bacterium
1. Design and Synthesis of Gene of interest
Step one, carrying out codon optimization on a nucleotide sequence of an L-pantoate lactone dehydrogenase encoding gene derived from Humibacter sp.BT305 (actinomycetes) according to codon preference of escherichia coli (E.coli) to obtain an L-pantoate lactone dehydrogenase modified gene sequence, wherein the nucleotide sequence is shown as SEQ ID No. 1;
and step two, carrying out codon optimization on the nucleotide sequence of the ketopantoate lactone reductase coding gene derived from the candida magnolifolia according to the codon preference of escherichia coli (E.coli) to obtain a D-ketopantoate lactone modified gene sequence, wherein the nucleotide sequence is shown as SEQ ID No. 2.
And step three, carrying out codon optimization on a nucleotide sequence coded by the glucose dehydrogenase derived from Burkholderia stabilis according to the codon preference of escherichia coli (E.coli) to obtain a modified gene sequence of the glucose dehydrogenase, wherein the nucleotide sequence is shown as SEQ ID No. 3.
And step four, carrying out codon optimization on the nucleotide sequence of the D-pantoate lactonohydrolase encoding gene derived from Fusarium moniliforme CGMCC0536 (Fusarium moniliforme) according to the codon preference of escherichia coli (E.coli) to obtain a modified gene sequence of the D-pantoate lactonohydrolase, wherein the nucleotide sequence is shown as SEQ ID NO. 4.
Step five, synthesizing nucleotide sequences shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4, and respectively adding XhoI and NdeI enzyme cutting sites, SacI and NotI enzyme cutting sites, XhoI and NdeI enzyme cutting sites and XhoI and NdeI enzyme cutting sites to prepare the target gene 1, the target gene 2, the target gene 3 and the target gene 4.
2. Construction of recombinant expression vectors
Step one, taking a DNA molecule of the target genome 1 as a template, carrying out PCR amplification on lpldh-for and lpldh-rev by using primers, carrying out electrophoresis on 1% agarose gel to separate PCR products, and recovering a gene fragment of the target genome 1 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
lpldh-for：GGAATTCCATATGATGAACCCGTGGTTTGAAAC
lpldh-rev：CCGCTCGAGTGCGCTTTCTGCTTCTGC
The PCR system was as follows:
the PCR process was as follows: pre-denaturation at 95 deg.C for 5min, denaturation at 95 deg.C for 30s, annealing at 57 deg.C for 30s, extension at 72 deg.C for 1min for 30s, circulating for 28 times, keeping at 72 deg.C for 10min, cooling to 4 deg.C, and storing in refrigerator at 4 deg.C for use.
And step two, taking the DNA molecule of the target genome 2 as a template, carrying out PCR amplification on KPR-for and KPR-rev by adopting a primer pair, carrying out electrophoresis separation on a PCR product by using 1% agarose gel, and recovering the gene fragment of the target genome 2 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
KPR-for：
GGAATTCCATATGATGGCTAAAAACTTCTCTAACGTTGAATACC
KPR-rev：CCGCTCGAGCGGCAGGGTGTAACCACCGTCAAC
The PCR system was as follows:
the PCR process was as follows:
pre-denaturation at 95 deg.C for 5min, denaturation at 95 deg.C for 30s, annealing at 55 deg.C for 30s, extension at 72 deg.C for 1min, circulation for 28 times, keeping at 72 deg.C for 10min, cooling to 4 deg.C, and storing in refrigerator at 4 deg.C for use.
And step three, double-digesting the pRSFDuet-I plasmid and the gene fragment of the genome 1 by using restriction enzymes XhoI and NdeI, recovering a vector framework and a digested PCR product, connecting the vector framework and the digested PCR product by using T4 DNA ligase, transforming the connected product (named as pRSF-lpldhh) into E.coli BL21(DE3) competent cells, screening positive clones, extracting plasmids, sequencing and identifying, and naming the correct clone as E-pRSF-lpldh.
And step four, carrying out double digestion on pRSF-lpldh plasmid and a gene fragment of a genome 2 by using restriction enzymes SacI and NotI, recovering a vector skeleton and a digestion PCR product, connecting the vector skeleton and the digestion PCR product by using T4 DNA ligase, transforming the connection product (named as pRSFDuet-lpldh-kpr) into E.coli BL21(DE3) competent cells, screening positive clones, extracting plasmids for sequencing identification, and naming the correct clone as E-lpldh-kpr to obtain a single-plasmid two-enzyme recombinant expression vector, wherein the single-plasmid two-enzyme recombinant expression vector can be used for co-expressing L-pantoate dehydrogenase and ketopantoate reductase.
And step five, taking the DNA molecule of the target genome 3 as a template, carrying out PCR amplification on GDH-for and GDH-rev by adopting a primer pair, carrying out electrophoresis separation on a 1% agarose gel to obtain a PCR product, and recovering the gene fragment of the target genome 3 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
GDH-for：GGAATTCCATATGATGGCGGTAACGCAAACAG
GDH-rev：
CCGCTCGAGTTACTCAAACTCATTCCAGGAACG
The PCR system was as follows:
the PCR process was as follows:
pre-denaturation at 95 deg.C for 5min, denaturation at 95 deg.C for 30s, annealing at 56 deg.C for 30s, extension at 72 deg.C for 1min, circulation for 28 times, keeping at 72 deg.C for 10min, cooling to 4 deg.C, and storing in refrigerator at 4 deg.C for use.
And step six, double-enzyme digestion of the pET-21a plasmid and the gene fragment of the genome 3 by using restriction enzyme XhoI and NdeI, recovery of a vector framework and a PCR product, connection of the vector framework and the PCR product by using T4 DNA ligase, transformation of the connection product (named as pET-GDH) into an E-lpldh-kpr competent cell, screening of a positive clone, extraction of the plasmid, sequencing identification, and designation of the correct clone as E-lpldh-kpr-GDH to obtain a double-plasmid three-enzyme recombinant expression vector, wherein the double-plasmid three-enzyme recombinant expression vector can co-express L-pantoate lactone dehydrogenase, ketopantoate lactone reductase and glucose dehydrogenase.
Example 2 construction of recombinant engineering bacteria expressing D-pantolactone hydrolase
1. Design and Synthesis of Gene of interest
Carrying out codon optimization on a nucleotide sequence of a D-pantoate lactone hydrolase coding gene derived from Fusarium moniliforme CGMCC0536 according to the codon preference of escherichia coli (E.coli) to obtain a modified gene sequence of the D-pantoate lactone hydrolase, wherein the nucleotide sequence is shown as SEQ ID NO. 4;
synthesizing the nucleotide sequence shown in SEQ ID NO.4, and adding XhoI and NdeI enzyme cutting sites to prepare the target gene 4.
2. Construction of recombinant engineering bacteria
Taking a DNA molecule of a target genome 4 as a template, performing PCR amplification on HYD-for and HYD-rev by using primers, carrying out electrophoresis separation on a 1% agarose gel to obtain a PCR product, and recovering a gene fragment of the target genome 4 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
HYD-for：GGAATTCCATATGATGGCTAAGCTTCCTTCTAC
HYD-rev：CCGCTCGAGCTAATCATAGAGCTTGGGACCC
The PCR system was as follows:
the PCR process was as follows:
pre-denaturation at 95 deg.C for 5min, denaturation at 95 deg.C for 30s, annealing at 53 deg.C for 30s, extension at 72 deg.C for 1min for 30s, circulating for 28 times, keeping at 72 deg.C for 10min, cooling to 4 deg.C, and storing in refrigerator at 4 deg.C for use.
And step two, double-enzyme cutting the PCR products of the pET-28a plasmid and the genome 4 by using restriction enzyme XhoI and NdeI, recovering a carrier skeleton and the PCR products, connecting the carrier skeleton and the PCR products by using T4 DNA ligase, transforming the connection products (named as pET-hyd) into E.coli BL21(DE3) competent cells, screening positive clones, extracting plasmids, sequencing and identifying, and naming the correct clone as E-hyd.
Example 3 inducible expression of the recombinant engineered bacterium E-lpldh-kpr-GDH
The recombinant engineered bacterium E-lpldh-kpr-GDH prepared in example 1 was inoculated into 5mL of LB medium and cultured overnight at 37 ℃ and 200 rpm;
inoculating the seeds into 100mL of TB culture medium according to the inoculation amount of 2%, culturing for 2h under the conditions of 37 ℃ and 200rpm, adjusting the culture temperature to 30 ℃, and continuing culturing for 15 h;
6600rpm for 3min, discarding supernatant, washing with 0.2moL/L phosphoric acid buffer (pH6.5) for 2 times, and collecting thallus.
Wherein, the LB culture medium comprises the following components: 50ug/mL of ampicillin, 100mg/L of kanamycin, 5g/L of yeast powder, 10g/L of tryptone and 10g/L of sodium chloride.
The composition of TB medium is as follows: tryptone 20g/L, yeast powder 5g/L, sodium chloride 5g/L, glucose 2g/L, lactose 0.1-2.0g/L, ampicillin 50mg/L, and kanamycin 100 mg/L.
Example 4 inducible expression of recombinant engineered bacteria E-hyd
Inoculating the recombinant engineering bacterium E-hyd prepared in the embodiment 2 into 5mL LB culture medium, and culturing at 37 ℃ and 200rpm overnight to obtain seed liquid;
inoculating the seed solution into 100mL TB culture medium according to the inoculation amount of 2%, culturing for 2h under the conditions of 37 ℃ and 200rpm, adjusting the culture temperature to 30 ℃, and continuing to culture for 15 h; 6600rpm for 3min, discarding supernatant, washing with 0.2moL/L phosphoric acid buffer (pH6.5) for 2 times, and collecting thallus.
Wherein, the composition of the LB culture medium is as follows: 100mg/L kanamycin, 5g/L yeast powder, 10g/L tryptone and 10g/L sodium chloride.
The composition of TB medium is as follows: tryptone 20g/L, yeast powder 5g/L, sodium chloride 5g/L, glucose 2g/L, lactose 0.1-2.0g/L, kanamycin 100 mg/L.
Example 5 conversion of DL-pantoic acid lactone
Adding 130g of DL-pantolactone and 180g of glucose into a reaction vessel, adding water until the total volume is 1L, and stirring for dissolving; the solution pH was adjusted to 6.2 with 20-25% ammonia, the temperature was raised to 37 ℃, the recombinant engineered bacterial cells (OD ═ 2) collected in example 1 were added, and the mixed solution was left at 37 ℃ and stirred to react for 30 hours, yielding a reaction solution. The high performance liquid chromatography detection is carried out on the reaction liquid, the final concentration of D-pantolactone is 124.67g/L, the conversion rate of DL-pantolactone is 95.9%, and the ee value is 91.8%.
Example 6 conversion of DL-pantolactone
Adding 130g of DL-pantolactone and 180g of glucose into a reaction vessel, adding water until the total volume is 1L, and stirring for dissolving; after adjusting the pH of the solution to 6.2 with 20-25% aqueous ammonia and raising the temperature to 37 ℃, the bacterial cells (OD 2) collected in example 1 and 50mM NADPH (reaction system concentration) were added, and the mixture was left at 37 ℃ and stirred for 30 hours to obtain a reaction solution. The reaction solution is subjected to high performance liquid chromatography detection, the final concentration of D-pantolactone is 124.93g/L, the conversion rate of DL-pantolactone is 97.8%, and the ee value is 95.6%.
Example 7 conversion of DL-pantoic acid lactone
Adding 130g of DL-pantolactone and 180g of glucose into a reaction vessel, adding water until the total volume is 1L, and stirring for dissolving; the solution pH was adjusted to 6.2 with 20-25% ammonia water, the temperature was raised to 37 ℃, then the recombinant engineered bacterial cells collected in example 1 (OD ═ 2) and the recombinant engineered bacterial cells collected in example 2 (OD ═ 3) were added, and the mixed solution was left at 37 ℃ and stirred to react for 30 hours, thereby obtaining a reaction solution. The reaction solution is subjected to high performance liquid chromatography detection, the final concentration of D-pantoic acid is 147.956g/L, and the conversion rate of DL-pantoic acid lactone is 99.97%.
And (3) passing the reaction solution through a ceramic membrane, collecting clear solution of the ceramic membrane, passing the clear solution through a nanofiltration membrane, collecting clear solution of the nanofiltration membrane, adjusting the pH to 1.5 by using concentrated sulfuric acid, and standing for 30min to obtain a D-pantolactone solution, wherein the concentration of the D-pantolactone is 129.96g/L, and the ee value is 99.94%.
Example 8 conversion of DL-pantoic acid lactone
Adding 130g of DL-pantolactone and 180g of glucose into a reaction vessel, adding water until the total volume is 1L, and stirring for dissolving; the ph of the solution was adjusted to 6.2 with 20 to 25% aqueous ammonia, the temperature was raised to 37 ℃, the recombinant engineered bacterial cell (OD ═ 2) collected in example 1 and the recombinant engineered bacterial cell (OD ═ 2) collected in example 2 were added, and the mixture was stirred at 37 ℃ for 30 hours to obtain a reaction solution. The reaction solution was subjected to chromatographic detection, and the final concentration of D-pantoic acid was 146.37g/L, and the conversion of DL-pantoic lactone was 98.9%.
And (3) passing the reaction solution through a ceramic membrane, collecting a ceramic membrane clear solution and a nanofiltration membrane, collecting a nanofiltration membrane clear solution, adjusting the pH to be about 1.5, and standing for 30min to obtain a D-pantolactone solution, wherein the D-pantolactone concentration is 129.02g/L, and the ee value is 98.5%.
The above description of the specific embodiments of the present invention is not intended to limit the present invention, and those skilled in the art may make various changes and modifications according to the present invention without departing from the spirit of the present invention, which is defined in the appended claims.
Sequence listing
<110> Anhui Hua constant Biotech, Inc
Bayannur Huaheng Biotechnology Co.,Ltd.
QINHUANGDAO HUAHENG BIOENGINEERING Co.,Ltd.
HEFEI HUAHENG BIOLOGICAL ENGINEERING Co.,Ltd.
<120> recombinant engineering bacterium, construction method and application thereof
<150> 2020110463081
<151> 2020-09-29
<150> 2021109427873
<151> 2021-08-17
<150> 2021110879871
<151> 2021-09-16
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1176
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
atggctaaaa acgctttctt cgaaaccgtt gctgaagctc agcgtcgtgc taaaaaacgt 60
ctgccgaaat ctgtttacgc tgctctggtt gctggttctg aaaaaggtct gaccgttgac 120
gacaacgttg ctgctttctc tgaactgggt ttcgctccgc acgctgctgg tctgtctgac 180
aaacgtgaaa tgtctaccac catcatgggt caggacatct ctctgccggt tatgatctct 240
ccgaccggtg ttcaggctgt tcacccggac ggtgaagttg ctgttgctcg tgctgctgct 300
gctcgtggta ccgctatcgg tctgtcttct ttcgcttcta aatctatcga agaagttgct 360
gctgctaacc cgcaggtttt cttccagatg tactgggttg gttctcgtga cgttctgctg 420
cagcgtatgg aacgtgctcg tgctgctggt gctaaaggtc tgatcatcac caccgactgg 480
tctttctctt acggtcgtga ctggggttct ccgtctatcc cggaaaaaat ggacctgaaa 540
gctatgttcc agttcgctcc ggaaggtatc atgcgtccga aatggctgct ggaattcgct 600
aaaaccggta aaatcccgga cctgaccacc ccgaacctgg ctgctccggg tcagccggct 660
ccgaccttct tcggtgctta cggtgaatgg atgcagaccc cgctgccgac ctgggaagac 720
atcgcttggc tgcgtgaaca gtggggtggt ccgttcatgc tgaaaggtat catgcgtatc 780
gacgacgcta aacgtgctgt tgacgctggt gtttctgcta tctctgtttc taaccacggt 840
ggtaacaacc tggacggtac cccggctccg atccgtgttc tgccgggtat cgctgaagct 900
gttggtgacc aggttgaagt tgttctggac ggtggtatcc gtcgtggtgg tgacgttgtt 960
aaagctctgg ctctgggtgc taaagctgtt atgctgggtc gtgcttacct gtggggtctg 1020
tctgctaacg gtcaggctgg tgttgaaaac gttctggacc tgatgcgtat gggtatcgac 1080
tctggtctga tgggtctggg tcactcttct atcaccgaac tgtctccggc tgacctggtt 1140
atcccggaag gtttcacccg taccctgggt gcttct 1176
<210> 2
<211> 849
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
atggctaaaa acttctctaa cgttgaatac ccggctccgc cgccggctca caccaaaaac 60
gaatctctgc aggttctgga cctgttcaaa ctgaacggta aagttgcttc tatcaccggt 120
tcttcttctg gtatcggtta cgctctggct gaagctttcg ctcaggttgg tgctgacgtt 180
gctatctggt acaactctca cgacgctacc ggtaaagctg aagctctggc taaaaaatac 240
ggtgttaaag ttaaagctta caaagctaac gtttcttctt ctgacgctgt taaacagacc 300
atcgaacagc agatcaaaga cttcggtcac ctggacatcg ttgttgctaa cgctggtatc 360
ccgtggacca aaggtgctta catcgaccag gacgacgaca aacacttcga ccaggttgtt 420
gacgttgacc tgaaaggtgt tggttacgtt gctaaacacg ctggtcgtca cttccgtgaa 480
cgtttcgaaa aagaaggtaa aaaaggtgct ctggttttca ccgcttctat gtctggtcac 540
atcgttaacg ttccgcagtt ccaggctacc tacaacgctg ctaaagctgg tgttcgtcac 600
ttcgctaaat ctctggctgt tgaattcgct ccgttcgctc gtgttaactc tgtttctccg 660
ggttacatca acaccgaaat ctctgacttc gttccgcagg aaacccagaa caaatggtgg 720
tctctggttc cgctgggtcg tggtggtgaa accgctgaac tggttggtgc ttacctgttc 780
ctggcttctg acgctggttc ttacgctacc ggtaccgaca tcatcgttga cggtggttac 840
accctgccg 849
<210> 3
<211> 1476
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
atggctgtaa cacaaactgc gcaggcatgt gacctggtta tttttggcgc taagggagat 60
cttgcccgta gaaagctgct gccgtccctg taccagctgg agaaggctgg ccaactgaat 120
ccggatacgc gtattatcgg cgtgggccgt gcggattggg ataaagcggc gtacaccaag 180
gtggtgcgcg aagctttaga gacattcatg aaagaaacca tcgacgaggg tttatgggat 240
accctgtctg cgcgtttgga tttttgtaat ctggacgtga acgacacggc ggcgtttagc 300
cgtcttggtg ctatgctgga ccagaaaaac cgcatcacca ttaactactt cgccatgccg 360
ccatccacct tcggcgcgat ctgcaaaggc ctgggtgagg ccaaactgaa cgcgaaaccg 420
gcacgcgtgg tgatggaaaa gccgctgggc acctcgctgg ctacctcgca agaaattaat 480
gaccaagttg gcgaatactt cgaggagtgc caggtctacc gcatcgacca ctatctgggt 540
aaggagactg tgctgaacct gttagcgctg cgttttgcaa atagcttgtt cgtgaataac 600
tgggacaacc gtacgatcga ccatgttgag atcacggtgg ctgaagaggt cggtattgaa 660
ggccgttggg gttacttcga taaggccggc cagatgcgtg acatgattca aaaccacctg 720
ttgcaaattc tgtgtatgat cgccatgagc ccgccctctg atctgagcgc agactcgatc 780
cgcgacgaga aggtcaaagt gctgaaaagc cttagacgta tcgatcgttc taatgttcgc 840
gaaaagaccg tacgtggtca atataccgct ggttttgcgc agggtaaaaa agttccgggt 900
tatttggagg aggagggcgc gaacaagtcc tccaacaccg aaaccttcgt tgcgattcgt 960
gttgatatcg ataactggcg ttgggcaggc gttccgtttt atctgcgcac cggtaagcgt 1020
ctgccgacca agtgcagcga agtggttgtg tatttcaaaa ccccggaact gaacctgttc 1080
aaagaaagct ggcaggattt gccacagaac aaattgacca tccgtttgca gccggatgag 1140
ggcgttgaca tccaagttct gaacaaggtg ccgggtctgg accacaaaca taacttgcag 1200
atcactaagt tggacctgtc ttacagcgaa acctttaacc agacccatct ggcggacgcc 1260
tacgaacgtc tgttgctcga gacgatgcgt gggattcaag cgctcttcgt acgccgagac 1320
gaggttgagg aggcgtggaa atgggttgac agcattacgg aagcgtgggc gatggacaat 1380
gatgcaccga aaccttatca ggcgggtacg tggggtccgg ttgcaagcgt cgctatgatt 1440
actcgcgatg gtcgtagctg gaatgaattt gaataa 1476
<210> 4
<211> 1146
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
atggcaaaac taccctcaac agctcaaata attgatcaga aatccttcaa cgtgctgaag 60
gacgtgccac cgccagcggt ggctaatgat tccttggttt ttacctggcc tggtgttacg 120
gaggaaagct tggttgaaaa accgtttcac gtgtacgatg aagagttcta cgacgtgatc 180
ggcaaggacc cgtccttgac cctgatcgct accagtgata cggacccgat tttccatgaa 240
gccgtcgtgt ggtatccgcc gaccgaggag gtgttctttg ttcagaacgc aggcgctccg 300
gctgcgggca ctggtctgaa caaaagcagc attatccaga aaatttcgct gaaagaagcg 360
gatgaggttc gtaagggcaa gaaagatgag gttaaagttg cagttgttga ttctaatccg 420
caggtcatca acccgaacgg cggtacctat tacaaaggca acattatctt cgcgggcgaa 480
ggtcaaggtg acgatgtgcc gagcgcactg tacctgatga atccgctccc gccgtacaac 540
accactacgc tgctgaataa ctattttggt cgccagttca acagcttgaa cgatgttggt 600
atcaacccgc gtaatggcga cctgtatttc accgacaccc tttatggcta tctgcaggat 660
tttcgtccgg ttccaggtct gcgtaaccaa gtctaccgct acaacttcga tacgggtgcg 720
gtgacggtgg tcgccgacga cttcaccttg ccgaacggta ttggcttcgg tccggatggt 780
aaaaaggtgt atgttactga cacaggcatc gccctgggtt tttacggccg caacctgagc 840
tccccggcgt ctgtgtacag ctttgacgta aatcaagatg gcaccttaca aaacagaaag 900
acctttgcgt atgtcgcgag ctttatcccg gacggggttc acaccgacag caaaggtcgt 960
gtttacgcag gatgcggtga cggcgttcat gtgtggaatc cgtctggcaa gctgatcggt 1020
aagatctata ccggcaccgt tgcggcaaat ttccagttcg ctggtaaggg ccgtatgatt 1080
attaccggtc aaaccaagct attttacgtg accttgggtg cgtctggtcc gaaactgtac 1140
gactaa 1146
Claims (10)
1. A recombinant vector contains a recombinant vector, wherein the nucleotide sequence of the L-pantolactone dehydrogenase modification gene sequence is shown as SEQ ID No.1, the nucleotide sequence of the ketopantolactone reductase modification gene sequence is shown as SEQ ID No.2, the nucleotide sequence of the glucose dehydrogenase modification gene sequence is shown as SEQ ID No.3, and the nucleotide sequence of the D-pantolactone hydrolase modification gene sequence is shown as SEQ ID No. 4.
2. The recombinant vector according to claim 1, wherein the recombinant vector optionally comprises any one of a fifth recombinant vector and a sixth recombinant vector, wherein the fifth recombinant vector comprises a nucleotide sequence of an L-pantoate lactone dehydrogenase-modified gene sequence shown in SEQ ID No.1 and a nucleotide sequence of a ketopantoate lactone reductase-modified gene sequence shown in SEQ ID No.2, the sixth recombinant vector comprises a nucleotide sequence of an L-pantoate lactone dehydrogenase-modified gene sequence shown in SEQ ID No.1, a nucleotide sequence of a ketopantoate lactone reductase-modified gene sequence shown in SEQ ID No.2, a nucleotide sequence of a glucose dehydrogenase-modified gene sequence shown in SEQ ID No.3 and a nucleotide sequence of a D-pantoate lactone hydrolase-modified gene sequence shown in SEQ ID No. 4.
3. A recombinant engineered bacterium comprising any one or combination of a first recombinant vector capable of expressing L-pantolactone dehydrogenase, a second recombinant vector expressing ketopantolactone reductase, a third recombinant vector expressing glucose dehydrogenase and a fourth recombinant vector expressing D-pantolactone hydrolase;
and/or the recombinant engineering bacteria comprise a fifth recombinant vector capable of co-expressing L-pantoate lactone dehydrogenase and ketopantoate lactone reductase;
and/or the recombinant engineering bacteria comprise a sixth recombinant vector capable of co-expressing L-pantoate lactone dehydrogenase, ketopantoate lactone reductase, glucose dehydrogenase and D-pantoate lactone hydrolase.
4. The recombinant engineered bacterium of claim 3, wherein the recombinant engineered bacterium comprises a fifth recombinant vector capable of co-expressing L-pantolactone dehydrogenase, ketopantolactone reductase and a third recombinant vector expressing glucose dehydrogenase; preferably, the recombinant engineering bacteria also comprise a fourth recombinant vector for expressing the D-pantolactone hydrolase, or are combined with a second recombinant engineering bacteria for expressing the fourth recombinant vector for expressing the D-pantolactone hydrolase.
5. A construction method of recombinant engineering bacteria comprises the following steps:
(1) respectively introducing any one or combination of an L-pantolactone dehydrogenase modification gene sequence, a ketopantolactone reductase modification gene sequence, a glucose dehydrogenase modification gene sequence and a D-pantolactone hydrolase modification gene sequence into a vector to obtain a recombinant vector;
(2) and (3) introducing the obtained recombinant vector into a host cell to obtain the recombinant engineering bacterium.
6. An inducible expression method of recombinant engineering bacteria comprises the following steps:
s-1, inoculating the recombinant engineering bacteria into an LB culture medium according to the inoculation amount of 1-5%, and culturing for 6-16h at the temperature of 30-40 ℃ and at the speed of 50-500rpm to obtain a first-stage seed solution;
s-2, inoculating the primary seed solution into a TB culture medium according to the inoculation amount of 1-5%, culturing for 6-20h at the temperature of 25-40 ℃ and at the speed of 50-500rpm, centrifuging, washing with a phosphate buffer solution, and collecting thalli.
7. A preparation method of D-pantoic acid lactone comprises the following steps: putting DL-pantoic acid lactone with the concentration of 10-300g/L into a reaction system with glucose and the OD value of the recombinant engineering bacteria of 1-5, and reacting for 20-40h under the conditions of 30-40 ℃ and pH5-7 to prepare the D-pantoic acid lactone.
8. The process according to claim 7, wherein the recombinant engineered bacteria can express L-pantolactone dehydrogenase, ketopantolactone reductase and glucose dehydrogenase; preferably, recombinant engineering bacteria for expressing D-pantolactone hydrolase can be added.
9. The production method according to any one of claims 7 to 8, wherein the ratio of DL-pantoic acid lactone: the molar ratio of formic acid is 1 (0.8-1.2), preferably 1 (0.9-1.1).
10. Use of the recombinant engineered bacterium of any one of claims 3-4 for the preparation of D-pantolactone.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020110463081 | 2020-09-29 | ||
| CN202011046308.1A CN113106129A (en) | 2020-09-29 | 2020-09-29 | Preparation method of D pantolactone with high conversion rate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114457130A true CN114457130A (en) | 2022-05-10 |
Family
ID=76709094
Family Applications (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011046308.1A Withdrawn CN113106129A (en) | 2020-09-29 | 2020-09-29 | Preparation method of D pantolactone with high conversion rate |
| CN202110940857.1A Pending CN114426977A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
| CN202110941962.7A Pending CN114426978A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
| CN202110942787.3A Pending CN114426979A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
| CN202110942171.6A Pending CN115044594A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
| CN202111084984.2A Pending CN115011623A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111087303.8A Pending CN114774446A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111087987.1A Pending CN115029364A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111085127.4A Pending CN115011624A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
| CN202111133610.5A Withdrawn CN114457128A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111135111.XA Withdrawn CN114457130A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111132818.5A Withdrawn CN114457127A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111135083.1A Withdrawn CN114457129A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
Family Applications Before (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011046308.1A Withdrawn CN113106129A (en) | 2020-09-29 | 2020-09-29 | Preparation method of D pantolactone with high conversion rate |
| CN202110940857.1A Pending CN114426977A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
| CN202110941962.7A Pending CN114426978A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
| CN202110942787.3A Pending CN114426979A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
| CN202110942171.6A Pending CN115044594A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
| CN202111084984.2A Pending CN115011623A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111087303.8A Pending CN114774446A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111087987.1A Pending CN115029364A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111085127.4A Pending CN115011624A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
| CN202111133610.5A Withdrawn CN114457128A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111132818.5A Withdrawn CN114457127A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
| CN202111135083.1A Withdrawn CN114457129A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
Country Status (1)
| Country | Link |
|---|---|
| CN (13) | CN113106129A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113604371B (en) * | 2021-08-03 | 2023-06-16 | 合肥学院 | Yeast strain HF-21 and method for preparing D-pantolactone by double-phase catalysis thereof |
| CN115044638A (en) * | 2022-07-21 | 2022-09-13 | 上海奥萝拉医药科技有限公司 | Preparation method of D-pantolactone with high optical selectivity |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1597962A (en) * | 2004-08-03 | 2005-03-23 | 江南大学 | D-Pantothe internal ester hydrolase c DNA and its clone expression and application |
| CN101128577A (en) * | 2004-12-22 | 2008-02-20 | 密歇根生物技术研究所 | Recombinant microorganisms for increased production of organic acids |
| WO2008046328A1 (en) * | 2006-10-19 | 2008-04-24 | East China University Of Science And Technology | A levorotatory lactonohydrolase producing strain and its use for producing chiral oxyacid |
| CN104388373A (en) * | 2014-12-10 | 2015-03-04 | 江南大学 | Construction of escherichia coli system with coexpression of carbonyl reductase Sys1 and glucose dehydrogenase Sygdh |
| CN110423717A (en) * | 2019-05-05 | 2019-11-08 | 杭州鑫富科技有限公司 | Multienzyme recombinant cell and multienzyme cascade the method for catalyzing and synthesizing D-pantoyl lactone |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105132487B (en) * | 2015-07-24 | 2019-04-09 | 雅本化学股份有限公司 | A kind of regenerating coenzyme system and preparation method thereof |
| CN106676051B (en) * | 2016-10-31 | 2019-07-05 | 中国科学院微生物研究所 | It is a kind of to prepare the method and its application for efficiently synthesizing pantothenic acid genetic engineering bacterium |
| CN109456908A (en) * | 2018-11-15 | 2019-03-12 | 江南大学 | A kind of genetic engineering bacterium producing D-pantoyl lactone hydrolase and its construction method and application |
| CN110396505A (en) * | 2019-05-05 | 2019-11-01 | 杭州鑫富科技有限公司 | Ketone group pantoic acid lactone reductase and its application |
| CN110408604B (en) * | 2019-08-14 | 2020-11-27 | 华东理工大学 | Formate dehydrogenase mutant with improved substrate affinity and coenzyme affinity |
| CN115044638A (en) * | 2022-07-21 | 2022-09-13 | 上海奥萝拉医药科技有限公司 | Preparation method of D-pantolactone with high optical selectivity |
-
2020
- 2020-09-29 CN CN202011046308.1A patent/CN113106129A/en not_active Withdrawn
-
2021
- 2021-08-17 CN CN202110940857.1A patent/CN114426977A/en active Pending
- 2021-08-17 CN CN202110941962.7A patent/CN114426978A/en active Pending
- 2021-08-17 CN CN202110942787.3A patent/CN114426979A/en active Pending
- 2021-08-17 CN CN202110942171.6A patent/CN115044594A/en active Pending
- 2021-09-16 CN CN202111084984.2A patent/CN115011623A/en active Pending
- 2021-09-16 CN CN202111087303.8A patent/CN114774446A/en active Pending
- 2021-09-16 CN CN202111087987.1A patent/CN115029364A/en active Pending
- 2021-09-16 CN CN202111085127.4A patent/CN115011624A/en active Pending
- 2021-09-27 CN CN202111133610.5A patent/CN114457128A/en not_active Withdrawn
- 2021-09-27 CN CN202111135111.XA patent/CN114457130A/en not_active Withdrawn
- 2021-09-27 CN CN202111132818.5A patent/CN114457127A/en not_active Withdrawn
- 2021-09-27 CN CN202111135083.1A patent/CN114457129A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1597962A (en) * | 2004-08-03 | 2005-03-23 | 江南大学 | D-Pantothe internal ester hydrolase c DNA and its clone expression and application |
| CN101128577A (en) * | 2004-12-22 | 2008-02-20 | 密歇根生物技术研究所 | Recombinant microorganisms for increased production of organic acids |
| WO2008046328A1 (en) * | 2006-10-19 | 2008-04-24 | East China University Of Science And Technology | A levorotatory lactonohydrolase producing strain and its use for producing chiral oxyacid |
| CN104388373A (en) * | 2014-12-10 | 2015-03-04 | 江南大学 | Construction of escherichia coli system with coexpression of carbonyl reductase Sys1 and glucose dehydrogenase Sygdh |
| CN110423717A (en) * | 2019-05-05 | 2019-11-08 | 杭州鑫富科技有限公司 | Multienzyme recombinant cell and multienzyme cascade the method for catalyzing and synthesizing D-pantoyl lactone |
Non-Patent Citations (2)
| Title |
|---|
| DAYONG SI 等: "L-Pantoyl lactone dehydrogenase from Rhodococcus erythropolis: genetic analyses and application to the stereospecific oxidation of L-pantoyl lactone", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY * |
| 柳志强,孙志浩: "串珠镰孢霉D-泛解酸内酯水解酶基因的克隆及在大肠杆菌中的表达", 生物工程学报 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114457127A (en) | 2022-05-10 |
| CN114426979A (en) | 2022-05-03 |
| CN115029364A (en) | 2022-09-09 |
| CN115044594A (en) | 2022-09-13 |
| CN115011624A (en) | 2022-09-06 |
| CN113106129A (en) | 2021-07-13 |
| CN114774446A (en) | 2022-07-22 |
| CN114426977A (en) | 2022-05-03 |
| CN115011623A (en) | 2022-09-06 |
| CN114457129A (en) | 2022-05-10 |
| CN114457128A (en) | 2022-05-10 |
| CN114426978A (en) | 2022-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110423717B (en) | Multienzyme recombinant cell and method for synthesizing D-pantolactone by multienzyme cascade catalysis | |
| CN105274070A (en) | Mutant of 7 beta-hydroxyl steroid dehydrogenase, application of mutant and synthesis method | |
| CN114457130A (en) | Recombinant engineering bacterium and construction method and application thereof | |
| CN109735553A (en) | A kind of preparation method of anti-AIDS drug atazanavir intermediate | |
| CN114874964A (en) | Construction method and application of recombinant escherichia coli for high yield of 2' -fucosyllactose | |
| CN110396507B (en) | L-pantolactone dehydrogenase from Cneubacter physcomitrella | |
| CN113913399B (en) | Ketopantolactone reductase from Candida maltosa Xu316 | |
| CN113355367B (en) | Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid | |
| CN109706189B (en) | Preparation method of D-chiro-inositol | |
| CN109679978B (en) | Recombinant co-expression system for preparing L-2-aminobutyric acid and application thereof | |
| CN118028257A (en) | Mutant carbonyl reductase and application thereof in synthesis of (R) -configuration vitronectin | |
| CN109943542A (en) | A kind of alcohol dehydrogenase for the production of atazanavir intermediate | |
| CN114085820B (en) | Ketopantolactone reductase from Candida viswanathii | |
| CN113930457B (en) | Method for synthesizing (S) -citronellol by double enzyme coupling | |
| CN114525291B (en) | Carbonyl reductase and method for preparing (R) -4-chloro-3-hydroxybutyrate by using same | |
| CN115975964A (en) | High-activity ketopantolactone reductase mutant and coding gene and application thereof | |
| CN111705043B (en) | Ketoreductase mutant with improved catalytic activity and application thereof | |
| CN111690696B (en) | Method for preparing darunavir intermediate through biocatalysis | |
| CN110857444A (en) | Preparation method of scyllo-inositol | |
| CN110396506B (en) | L-pantolactone dehydrogenase derived from Nocardia asteroids and use thereof | |
| CN111635893A (en) | Ketoreductase and application thereof in production of darunavir intermediate | |
| CN111662889A (en) | Ketoreductase mutant for producing darunavir intermediate | |
| CN114806999B (en) | Genetically engineered bacterium and application thereof in preparing dihydrodaidzein | |
| CN114480315B (en) | Baeyer-Villiger monooxygenase and application thereof in brivaracetam synthesis | |
| CN118291408A (en) | Enzyme combination, recombinant engineering bacterium, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220510 |
|
| WW01 | Invention patent application withdrawn after publication |